<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298883</url>
  </required_header>
  <id_info>
    <org_study_id>584-2004</org_study_id>
    <nct_id>NCT00298883</nct_id>
  </id_info>
  <brief_title>Desensitization of Renal Transplant Candidates</brief_title>
  <official_title>Desensitization of Renal Transplant Candidates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial of the use of Myfortic to reduce anti-HLA alloantibody in patients waiting for renal
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-formed HLA antibodies prevent renal transplantation because of the risk of hyperacute
      rejection. We propose a prospective study evaluating the efficacy of Enteric Coated
      Mycophenolate Sodium (Myfortic) in decreasing the titers of anti-HLA alloantibodies in
      patients awaiting kidney transplantation. Myfortic is an immunosuppressant that inhibits the
      proliferation of B and T cells by blocking the enzyme inosine monophosphate dehydrogenase. We
      will attempt to determine whether a 6-week course of Myfortic adequately decreases the
      antibody reactivity to a level compatible with transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease in antibody reactivity</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CBC and CMP values &lt;/&gt; 2 times normal</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm, interventional trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic</intervention_name>
    <description>Myfortic 360mg PO BID for six weeks</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients on the deceased donor kidney transplant waiting list with panel reactive
             antibodies &gt;50% and living donor waiting list patients who have a history of a
             positive crossmatch (donor-specific antibodies) will be eligible for the study.

        Exclusion Criteria:

          -  Any subjects not meeting the Inclusion Criteria

          -  Subjects unable to attend weekly clinic visits for six weeks

          -  Inability to tolerate Myfortic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiro Fujita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2006</study_first_submitted>
  <study_first_submitted_qc>March 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2006</study_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal</keyword>
  <keyword>Transplant</keyword>
  <keyword>PRA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

